Roivant Sciences Ltd. (NASDAQ:ROIV) Q4 2021 Earnings Conference Call June 28, 2022 8:00 AM ET

Company Participants

Paul Davis - Head, Communications

Matt Gline - Chief Executive Officer

Richard Pulik - Chief Financial Officer

Frank Torti - Vant Chair

Eric Venker - President and Chief Operating Officer

Mayukh Sukhatme - President and Chief Investment Officer

Conference Call Participants

Dennis Ding - Jefferies

Yaron Werber - Cowen

Louise Chen - Fitzgerald

Neena Bitritto-Garg - Citi

David Risinger - SVB Securities

Corinne Jenkins - Goldman Sachs

Operator

Good day, and thank you for standing by. Welcome to Roivant’s Fourth Quarter and Fiscal Year 2021 Earnings Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded. [Operator Instructions]

I would now like to hand the conference over to your speaker today, Paul Davis, Head of Communications. Please go ahead.

Paul Davis

Good morning, and thank you for joining today's call to discuss Roivant's financial results and business updates for the fourth quarter and fiscal year ended March 31, 2022. I'm Paul Davis, the Head of Communications at Roivant. On the call today, we have Matt Gline, our Chief Executive Officer; Richard Pulik, our Chief Financial Officer; Frank Torti, our Vant Chair; Eric Venker, our President and Chief Operating Officer; and Mayukh Sukhatme, our President and Chief Investment Officer.

For those dialing in by phone, you can find the slides being presented today as well as the press release announcing these updates on our IR website at www.investor.roivant.com. We'll be providing the slide numbers as we present to help you follow along.

I would like to remind you that we will be making certain forward-looking statements during today's presentation and reflect our current views and expectations, including those related to our financial performance and the potential attributes of our products and product candidates. We strongly encourage you to review the information that we have filed with the SEC, including the earnings release and Form 10-K filed this morning for more information regarding these forward-looking statements and related risks and uncertainties. Matt Gline will review key business updates across Roivant in advance, including the commercial launch of VTAMA at Dermavant as well as Priovant and Aruvant today, and we'll provide a financial update. We will end the call with a Q&A session.

Without further ado, I'll hand it over to Matt.